

# Essex Investment Management Company, LLC

"Early Identification of Growth, Wherever Growth Exists"

#### **Investment Objective**

The Essex Research Strategy is comanaged by a team of investment professionals seeking growth equity opportunities across an all-cap universe. By employing fundamental top down economic and sector analysis with bottom-up stock picking skills, the strategy provides the investment team a wide framework in which to identify growth candidates regardless of market capitalization restraint.

#### **Investment Team**



Joe McNay





Steve Cutler President



Saralyn Sacks Senior VP



Anne Marie McMichael



Alex Forse

#### About Essex


**Essex Investment Management,** founded in 1976, has a singular focus as a boutique growth manager offering portfolio management services to both institutions and high net worth individuals. As of quarter end, Essex has 19 employees of whom 11 are investment professionals.

### **Essex Research Strategy**

#### Composite Returns as of 9/30/17

	Curre	t Year Annualized Returns					
	QTD	YTD	1 YR	3 YR	5 YR	10 YR	Since Inception*
Essex Research (Gross)	4.7%	18.4%	17.3%	11.9%	15.9%	9.6%	10.9%
Essex Research (Net)	4.5%	17.6%	16.2%	10.8%	14.8%	8.6%	9.8%
Russell 3000 Growth Index	5.9%	20.4%	21.9%	12.7%	15.2%	9.0%	9.6%
(*Inception: 2/1/05)							

#### Annualized Return versus Benchmark as of 9/30/17



5 Year Calendar Performance	2012	2013	2014	2015	2016
Essex Research (Gross)	19.0%	44.8%	14.1%	4.7%	5.0%
Essex Research (Net)	17.9%	43.5%	13.0%	3.7%	4.0%
Russell 3000 Growth	15.2%	34.2%	12.4%	5.1%	7.4%

#### Top Ten Holdings (9/30/17)(1)

Partition.	Martin La
Position	Weight
Callidus Software	3.6%
Delphi Automotive	3.6%
Check Point Software	3.4%
Ebay	2.9%
Apple	2.8%
Alphabet	2.8%
Everbridge	2.8%
Builders Firstsource	2.8%
Amazon	2.7%
Iteris	2.7%
Total	30.2%

#### (1)Top ten holdings and weightings for a typical Research Strategy portfolio (2)Characteristics for a typical Research strategy portfolio

#### Characteristics (9/30/17)(2)

	Essex Research Strategy	Russell 3000 Growth	
Market Cap (\$M)			
Weighted Average	75,944	187,485	
Median	5,803	1,895	
Dividend Yield (%)	0.5	1.3	
Price/Earnings	30.8	25.3	
P/E using FY1 Est	23.7	20.3	
Price/Cash Flow	20.1	16.2	
Price/Book	4.5	6.1	
Price/Sales	1.9	2.7	

#### IMPORTANT DISCLOSURE

Risks of Essex Research portfolios: Essex Research Composite portfolio returns may show a high level of variability and volatility. In addition to market risk, additional risks in these portfolios may result from Essex's selection of specific securities, since individual holdings may represent a significant percentage of a portfolio's holdings from time to time. Sources: portfolio characteristics, top ten holdings and sector weights calculated internally by Essex. Performance Calculations: performance returns are of the Essex Research Composite, inception 2/1/2005. The Essex Research Composite includes all actual, fee-paying, fully discretionary accounts managed by Essex to seek capital appreciation by investing in growth companies without regard to market capitalization. In pursuing its equity securities, some of which may be highly speculative. The use of leveraging, short positions and derivatives has not been used by any of the accounts. The Russell 3000® Growth Index consists of those securities in the Russell 3000® with a greater-than average growth orientation, and includes reinvestment of dividends. The Russell 3000® Growth Index is a copyrights related to its respective indexes. The volatility of the indices may be materially different from the individual performance attained by a specific investor. In addition, the Adviser's/Fund's holdings may differ significantly from the securities that comprise the indices. The indices have not been selected to represent an appropriate benchmark to compare an investor's performance, but rather are disclosed to allow for comparison of an investor's performance to that of certain well-known and widely recognized indices. An index is unmanaged, does not incur fees or expenses, and cannot be invested in directly. Companies in this index tend to exhibit higher price-tobook and price/earnings ratios, lower dividend yields, and higher forecasted growth values. Composite returns include the reinvestment of dividends and are presented in USD. Gross performance results presented are net of transaction costs, withholding taxes and direct expenses, but before management fees, custody fees and other indirect expenses. Net performance results are presented net of the maximum applicable management fees, transaction costs, withholding taxes and direct expenses, but before custody fees and other indirect expenses. This composite does not incur any performance-based fees. Actual returns will be reduced by investment advisory fees and any other additional fees and expenses. Essex's standard fee schedule is available on request and can be found in Part 2A of our Form ADV. Investment advisory fees are generally collected quarterly, which produces a compounding effect on the total rate of return net of management fees. The actual the standard schedule depending on a number of factors including account type and size. Past composite performance is not necessarily predictive of how an investors' individual account will perform. Wherever the potential for profit exists, there is also a potential



Essex Investment Management Company, LLC

125 High St. Suite 1803 Boston, MA 02110 (617) 342-3200 www.essexinvest.com

## Essex Research Strategy

#### **Investment Process**

Each analyst Identifies companies in their coverage sector that are exhibiting early signs of improving business conditions. The team fundamentally analyzes over 500 such companies each year.

#### The objective:

- Determine the catalysts for positive earnings/revenue change
- Assess the sustainability of the change
- Develop internal earnings estimates
- Ascertain whether the anticipated growth is reflected in the current price of stock

## Catalysts give rise to improving situations. Typical catalysts include:

- Corporate restructuring
- Industry consolidation
- Improving industry
- Market share gains
- New products


# Though each analyst's sleeve of sector expertise, the team builds a high conviction portfolio of best Ideas.

 Companies in different phases of growth and demonstrating diverse growth and valuation characteristics

#### Employ a disciplined sell system:

- Catalyst for improved growth has played out
- Price target reached
- Deterioration of company specific fundamentals
- Better opportunities within sector





#### Performance Disclosures

This material is for your private information. The views expressed are the views of Essex only through the period ended 9/30/17 and are subject to change based on market and other conditions. The information above does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. All material has been obtained from sources believed to be reliable, but its accuracy is not guaranteed.

Past performance is no guarantee of future results.

The Essex Research Strategy representative account has been selected on the basis that its investment objective, historical performance record, and growth characteristics are consistent with those accounts in the Essex Research Strategy composite. The portfolio's trades are executed in accordance with all other accounts in the composite.

The representative account is fully discretionary and has been in the Essex Research Strategy for at least three years.

#### **Holdings Disclosures**

The above information represents the top 10 holdings in the Essex Research Strategy as of 9/30/17 based on the aggregate dollar value. The specific securities identified and described do not represent all of the securities purchased, sold, or recommended for Essex Research Strategy, and the reader should not assume that investments in the securities identified and discussed were or will be profitable. All information is provided for informational purposes only and should not be deemed as a recommendation to buy the securities mentioned.